MaxiVAX appoints Scott Johnson as Board Director
Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott Johnson, M.D., as a Board Director. Dr Johnson was a Founder of The Medicines Company where he is currently Chief Medical Advisor and Vice President of Business Development. He is also a Founder and General Partner of JSB Partners, L.P., providing specialized investment banking and advisory services to biotechnology and pharmaceutical companies.
MaxiVAX appoints Antonio Perez as Chief Medical Officer
Geneva, Switzerland – 14 December, 2017 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of Antonio Perez MD Ph.D., as its Chief Medical Officer. He joins the company after holding senior medical positions at Novartis, Biogen Idec, Basilea, Almirall and Esteve. He has also been a medical advisor to many companies across Europe and the US.
MaxiVAX wins 2017 CTI Swiss Medtech Award
The 2017 CTI Swiss Medtech Award, presented at the Swiss Medtech Day on 13 June, has gone to the biotech company MaxiVAX. MaxiVAX and the Geneva University Hospitals received the CHF 15,000 prize for developing a new vaccine designed to help the immune system in cancer patients fight their own tumor cells. The award was presented by Federal Councillor Johann N. Schneider-Ammann before around 600 guests in the Kursaal, Bern.
Download the poster.
Maxivax is 1 of 3 companies nominated to receive the CTI Swiss Medtech Award 2017. The winner announcement and Award ceremony will be held in Bern during the Swiss Medtech Day, on June 13th 2017.
Maxivax is presenting the final data of the primary endpoint of its First-In-Man study at the ESMO 2016 congress in Copenhagen.
See the poster.
MaxiVAX announces promising results from its phase 1 anti-cancer clinical trial
Read the full press release.
Press Release: MaxiVAX appoints Dimitrios Goundis as Chief Executive Officer
Read the full press release.
Poster Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from MVX-ONCO-1 first-in-man Phase 1 Trial.
MaxiVAX will participate in the Bio-Europe 2015 conference, Munich, Germany, Nov 2-4, 2015
MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results" has been selected by the 18th ECCO - 40th ESMO European Cancer Congress Scientific Committee as a Poster in the poster session "Immunotherapy of Cancer" on 26 September 2015 from 16:45 to 18:45 in Hall C. The poster has also been selected for a new special session called Poster Spotlight from 17:15 to 18:15.